Clinical Trials Logo

Filter by:
NCT ID: NCT04060862 Terminated - Breast Cancer Clinical Trials

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

IPATunity150
Start date: November 15, 2019
Phase: Phase 3
Study type: Interventional

The open-label Phase Ib portion of this study will evaluate the safety and pharmacokinetics of ipatasertib in combination with palbociclib and fulvestrant to identify a dose of ipatasertib that can be combined with palbociclib and fulvestrant in the Phase III portion. The randomized Phase III portion of this study will evaluate the efficacy, safety, and patient-reported outcome (PRO) objectives of ipatasertib + palbociclib + fulvestrant compared with placebo + palbociclib + fulvestrant in patients with HR+ HER2-, locally advanced unresectable or metastatic breast cancer who had relapsed during adjuvant endocrine therapy or progressed during the initial 12 months of first-line endocrine therapy in locally advanced unresectable or metastatic breast cancer.

NCT ID: NCT04060563 Terminated - Diastasis Recti Clinical Trials

Frequency Specific Microcurrent for the Treatment of Diastasis Recti

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Determine if frequency specific microcurrent therapy improves pain management of DRA by 30% or greater.

NCT ID: NCT04060342 Terminated - Clinical trials for Non-small Cell Lung Cancer

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Start date: August 13, 2019
Phase: Phase 1
Study type: Interventional

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

NCT ID: NCT04060329 Terminated - Cystic Fibrosis Clinical Trials

Measuring and Improving Coproduction Using coopeRATE

Start date: December 2, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to identify new methods of measuring and improving collaborative goal setting between patients and clinicians in adult cystic fibrosis care.

NCT ID: NCT04060251 Terminated - Clinical trials for Total Knee Arthroplasty

Is There an Alternative to Immediate Home Physical Therapy Following Total Knee Arthroplasty

Start date: April 4, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate how different pre-operative therapeutic approaches affect quad strength and patient satisfaction after total knee replacements. There are three treatments groups: standard physical therapy protocol, the use of CyMedica NMES garments, and a telemedical home therapy program.

NCT ID: NCT04060225 Terminated - High Blood Pressure Clinical Trials

Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults

Start date: December 2, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to help further the understanding of the effects of commercially available high-caffeine containing coffee on blood pressure in healthy adult subjects.

NCT ID: NCT04060147 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

NCT ID: NCT04059666 Terminated - Clinical trials for Gastrointestinal Microbiome

Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas

Start date: March 5, 2019
Phase: N/A
Study type: Interventional

This clinical trial will compare stool and oral microbiome composition between infants fed breast milk or one of two infant formulas for a 60 day feeding period.

NCT ID: NCT04059302 Terminated - Insomnia Chronic Clinical Trials

Internet Cognitive Behavioral Therapy for Insomnia to Prevent Cardiovascular Disease

STOPCVD
Start date: September 20, 2019
Phase: N/A
Study type: Interventional

This randomized controlled trial will test the efficacy of online cognitive-behavioral therapy for insomnia (CBT-I) to improve markers of subclinical cardiovascular disease risk among middle aged adults (40-64 years) with chronic insomnia who are at moderate-to-high risk for cardiovascular disease. Multiple trials have revealed face to face and digital CBT-I improves insomnia symptoms and associated daytime functioning. However, CBT-I has not been tested as a primary prevention intervention to reduce risk for CVD. Mid-life adults are a high-risk group for the emergence of CVD with detrimental consequences pervading into older adulthood including reduced quality of life and greater health care costs. The investigators will evaluate whether online CBT-I affects vascular and cardiac function and structure at post-treatment and 8-week follow-up in a community-based sample. Hypothesis 1: Online CBT-I will improve indices of cardiovascular function and structure compared to a wait-list control group at post-treatment. Hypothesis 2: Improvements in indices of cardiovascular function and structure will be maintained at 8-week follow-up in the online CBT-I group.

NCT ID: NCT04059159 Terminated - Urinary Retention Clinical Trials

Connected Catheter - Safety and Effectiveness Study

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a sterile, extended-use device that resides fully internally to the male lower urinary tract for an intended use life of up to 7 days per catheter.